DeepMind’s Latest AlphaFold AI Model Revoluti...

In this episode, we examine the S&P 500's refusal to allow SpaceX's fast-track entry, which also impacts OpenAI and Anthropic’s IPO prospects. We also discuss Google's $920 million monthly deal with SpaceX for AI compute power and escalating enterprise spending on AI token budget ...  Show more

In this episode, we explore Alphabet's ambitious plan to raise $80 billion for AI development, including a major investment from Berkshire Hathaway. We also discuss Trump's recent executive order on AI regulation, GitHub's controversial pricing changes, and the shifting landscape ...  Show more

"Pharmaceutical Breakthroughs: The Cutting Edge of Biotechnology" - In this episode, we dive deep into the revolutionary world of biotechnology and its transformative impact on pharmaceuticals. Discover how cutting-edge innovations are reshaping drug development, accelerating vac ...  Show more

Max Jaderberg and Sergei Yakneen from Isomorphic Labs discuss how AI is enhancing drug discovery by treating biology as an information processing system. They share how advanced AI models like AlphaFold 3 are accelerating the pipeline and paving the way for a future of precision ...  Show more

Why is the process of creating a new and highly beneficial pharmaceutical drug so difficult? What are the hurdles researchers face when trying to identify a new drug? Why are side effects so challenging to predict? Why are pharmaceutical drugs so expensive? In today's episode, we ...  Show more

Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI i ...